Affordable Access

deepdyve-link
Publisher Website

Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.

Authors
  • Sadanand, Saheli1
  • Suscovich, Todd J1
  • Alter, Galit1
Type
Published Article
Journal
Annual Review of Medicine
Publisher
Annual Reviews
Publication Date
Jan 01, 2016
Volume
67
Pages
185–200
Identifiers
DOI: 10.1146/annurev-med-091014-090749
PMID: 26565674
Source
Medline
Keywords
License
Unknown

Abstract

HIV-1 poses immense immunological challenges to the humoral immune response because of its ability to shield itself and replicate and evolve rapidly. Although most currently licensed vaccines provide protection via the induction of antibodies (Abs) that can directly block infection ( 1 ), 30 years of HIV-1 vaccine research has failed to successfully elicit such Abs against globally relevant HIV strains. However, mounting evidence suggests that these broadly neutralizing antibodies (bNAbs) do emerge naturally in a significant fraction of infected subjects, albeit after years of infection, indicating that these responses can be selected naturally by the immune response but take long periods of time to evolve. We review the basic structural characteristics of broadly neutralizing antibodies and how they recognize the virus, and we discuss new vaccination strategies that aim to mimic natural evolution to guide B cells to produce protective Abs against HIV-1.

Report this publication

Statistics

Seen <100 times